Generating an iPSC Bank for HLA-Matched Tissue Transplantation Based on Known Donor and Recipient HLA Types  by Taylor, Craig J. et al.
Cell Stem Cell
SynthesisGenerating an iPSC Bank for HLA-Matched
Tissue Transplantation Based on Known Donor
and Recipient HLA TypesCraig J. Taylor,1,* Sarah Peacock,1 Afzal N. Chaudhry,2 J. Andrew Bradley,3 and Eleanor M. Bolton3
1Histocompatibility and Immunogenetics Laboratory
2Department of Renal Medicine
3Department of Surgery, University of Cambridge
Cambridge University Teaching Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0QQ, UK
*Correspondence: craig.taylor@addenbrookes.nhs.uk
http://dx.doi.org/10.1016/j.stem.2012.07.014
The likelihood for immunological rejection of Human Leukocyte Antigens (HLA)-mismatched induced plurip-
otent stem cells (iPSCs) limits their therapeutic potential. Here we show how a tissue bank from 150 selected
homozygous HLA-typed volunteers could match 93% of the UK population with a minimal requirement for
immunosuppression. Our model provides a practical approach for using existing HLA-typed samples to
generate an iPSC stem cell bank that circumvents prospective typing of a large number of individuals.Induced human pluripotent stem cells
(iPSCs) can be generated successfully
from a variety of readily obtainable adult
tissues, including skin and peripheral
blood, and have the capacity for exten-
sive expansion in vitro, while retaining
their pluripotency (Takahashi et al.,
2007; Yu et al., 2007; Park et al., 2008; Ei-
senstein, 2010). Under appropriate in vitro
conditions, iPSCs can be directed to
differentiate into a wide range of special-
ized cell types and tissues that have
the potential for future use in the replace-
ment of diseased or damaged tissues in
patients with conditions such as trauma,
diabetes, degenerative neurological dis-
orders, cardiovascular disease, and
metabolic deficiencies.
iPSCs could, in principle, be derived
directly from individual patients who
require therapy with the advantage of
ensuring immune identity and minimizing
the risk of transplant rejection. However,
producing autologous clinical grade cells
for individual patients would pose major
logistical difficulties and wide-scale appli-
cation is likely to be financially prohibitive.
An alternative to personalized iPSC
therapy would be to create a bank of
clinical grade iPSC lines that can be
expanded and differentiated for use in a
large number of patients. Ideally, such a
bank would be populated with iPSCs ob-
tained from healthy volunteer donors of
blood group O that are selected to maxi-
mize the opportunity for Human Leuko-
cyte Antigens (HLA)matching and therebyminimize the risk of allograft rejection
(Bradley et al., 2002; Taylor et al., 2011).
Because HLA genotypes are highly vari-
able within a population, a bank of several
thousand random donors would be
required to achieve a clinically beneficial
HLA match for a majority of intended
recipients. Since this would be impracti-
cable, an alternative approach is to create
an iPSC bank that comprises a limited
number of highly selected cell donors
with homozygous HLA types to enable
HLA matching for a majority of potential
recipients (Taylor et al., 2005). Experience
from organ and cord blood transplanta-
tion has shown that the most important
HLA loci to match for are HLA-A, -B, and
-DR (Opelz and Do¨hler, 2007; Johnson
et al., 2010; Kurtzberg et al., 2008) and
that matching for these loci reduces the
incidence of allograft rejection and the
requirement for exogenous immunosup-
pression (Taylor et al., 1993; Opelz and
Do¨hler, 2010a, 2010b). Assuming that a
single pluripotent stem cell line can
provide cells or tissue for a large number
of potential recipients, we have calculated
previously that ten embryonic stem cell
lines with homozygous HLA haplotypes
identified from 10,000 HLA-typed individ-
uals representing UK potential donors
could provide a zero HLA-A, -B, and -DR
mismatch for around 38% of the UK pop-
ulation (Taylor et al., 2005). Nakatsuji et al.
(2008) estimated that 50 donors selected
from a population of 24,000 individuals
would be required to provide HLA-Cell Stem Cell 1matched tissue for 90.7% of the Japa-
nese population. Similarly, Okita et al.
(2011) calculated that 140 unique HLA
homozygous donors could provide a
match for 90% of the Japanese popula-
tion, but achieving this level of matching
would require screening of 160,000 Japa-
nese volunteer iPSC donors. Moreover,
Gourraud et al. (2012) developed a proba-
bilistic model to determine the number of
donors required to construct a bank of
HLA-haplotype-matched iPSCs in popu-
lations from four ancestry backgrounds.
They identified that a future bank com-
prising iPSC lines representing the 20
most frequent HLA haplotypes in each
population would require screening of
26,000 volunteer donors for European
Americans and 110,000 donors for
African Americans, and that this would
achieve matching for 50% and 22% of
the recipient populations, respectively.
These analyses confirm the potential clin-
ical utility of a small but highly selected
number of cell donors, but this would
require large-scale concerted world-
wide collaboration (Gourraud et al.,
2012), and does not offer a practical solu-
tion to identifying such donors from within
the general population, which would
require prospective HLA typing of several
thousand volunteers. This would be
expensive and the efficacy of the
approach would be dependent on the
chance finding of the desired homozy-
gous HLA haplotypes within the screened
population.1, August 3, 2012 ª2012 Elsevier Inc. 147
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a different approach that overcomes the
above limitations and offers a practical
solution for identifying individuals with
the optimal combination of HLA types
for populating an iPSC bank that, unlike
previous approaches, does not rely on
prospective typing of a large number of
individuals. While previous approaches
have relied on the chance finding of HLA
types with varying utility for matching
from within a large population, we,
instead, have compiled a list of existing
potential iPSC donor types ranked ac-
cording to their optimal utility. We first
determined the minimum number of theo-
retical homozygous HLA-A, -B, -DR
combinations that collectively can
provide an HLA match for all potential
UK recipients. We then interrogated
a database of over 17 million HLA-typed
healthy individuals, who have volunteered
as potential stem cell donors in the Bone
Marrow Donors Worldwide (BMDW)
registry, to determine whether individuals
bearing the desired homozygous HLA
combinations were accessible for con-
structing an iPSC bank with maximum
utility for HLA matching the UK
population.
Identification of the Most Useful
Theoretical Homozygous HLA-A, -B,
and -DR Combinations for HLA
Matching
The HLA type of an individual comprises
a pair of coexpressed haplotypes, each
consisting of an HLA-A, an HLA-B, and
an HLA-DR gene (in simple terms). The
combination of HLA-A, -B, and -DR genes
is not random because of genetic recom-
bination and external pressures from
environmental factors resulting in linkage
disequilibrium. These factors favor the
existence of certain HLA allele combina-
tions and ensure that other combinations
do not exist. While data for the frequency
of individual HLA specificities expressed
within populations are available, this
does not allow prediction of the existence
and frequency of all heterozygous HLA-A,
-B, and -DR combinations (i.e., HLA
types). Therefore, as a surrogate data-
base of existing HLA types representative
of the UK population that might benefit
from iPSC therapy, we obtained, from
NHS Blood and Transplant, the HLA-A,
-B, and -DR types of 10,000 anonymized
consecutive UK deceased organ donors148 Cell Stem Cell 11, August 3, 2012 ª2012typed between 1994 and 2009 (Johnson
et al., 2010).
According to the WHO HLA nomencla-
ture report (Marsh et al., 2010), there are
21 HLA-A, 44 HLA-B and 15 HLA-DR split
specificities (listed in Table S1). We have
calculated that these specificities could
generate a total of 13,860 HLA-A, -B,
and -DR combinations, each representing
a potential homozygous HLA-typed iPSC
donor. These 13,860 HLA combinations
were ranked for their ability to provide
a zero HLA-A, HLA-B, and HLA-DR gene
mismatch with the HLA types of the
10,000 deceased UK organ donors (rep-
resenting potential iPSC recipients), using
a computer algorithm (available on re-
quest) that determined both the frequency
of each HLA type within the 10,000 organ
donors and the number of HLA types for
which it would provide a zero mismatch.
Of the 13,860 theoretical homozygous
HLA combinations, 4,757 (34.3%) pro-
vided a zero HLA mismatch for one or
more (range 1–1,687) of the HLA types
of potential UK recipients. The remaining
9,103 HLA combinations were not repre-
sented within the 10,000 organ donors.
The two highest-ranking homozygous
HLA combinations were HLA-A1, -B8,
and -DR17(3), and HLA-A2, -B44(12),
and -DR4, both sets of which are
conserved HLA haplotypes commonly
found in white Europeans and, in this
analysis, provided a zero HLA mismatch
for 16.9% and 10.2% of potential
recipients, respectively (Table S2A). It is
important to note that the majority of the
population are heterozygous and many
individuals express both of these HLA
haplotypes; for a fully HLA-A, -B, and
-DR heterozygous individual, eight
different theoretical homozygous combi-
nations will each provide a zero HLA
mismatch (Table S2A). The common
HLA specificities such as HLA-A1, -A2,
and -A3 (phenotype frequency 34.2%,
49.8%, and 26.0%, respectively, Table
S1) dominate the highest-ranking theoret-
ical homozygous HLA combinations
(Table S2A). Beyond the first three highest
rankedHLA-A, -B, and -DR combinations,
the theoretical homozygous HLA types
that can provide a zero HLA mismatch
could not have been readily predicted
from published population HLA haplotype
frequencies alone, because of the com-
plexity arising from the mixture of homo-
zygous and heterozygous HLA-A, -B,Elsevier Inc.and -DR loci, including a high proportion
of nonconserved HLA haplotypes present
in the general population.
Table S2A shows that individual HLA
specificities (e.g., HLA-A1, -A2, -A3, -B7,
and-B8) with a high population phenotype
frequency are present in numerous
different HLA-A, -B, and -DR combina-
tions, and on average there were 6.8
zero-mismatched homozygous HLA
combinations identified for each recipient
HLA type.
Determination of the Minimum
Number of Theoretical Homozygous
HLA-A, -B, and -DR Combinations
Needed to Match Potential UK
Recipients
To determine the minimum number of
theoretical homozygous HLA-A, -B, and
-DR combinations that would provide an
HLA match for 100% of potential recipi-
ents (represented by the 10,000 organ
donors), the HLA-A, -B, and -DR combi-
nation with the highest number of zero
HLA-mismatched recipients was identi-
fied and matched recipients were then
censored from the recipient population.
The next HLA combination to provide
the greatest number of zero HLA-A, -B,
and -DR mismatches in the remaining
recipients was then identified and the
recipients censored, and the process
repeated until an HLA match had been
identified for all 10,000 potential recipi-
ents. A minimum of 405 theoretical homo-
zygous HLA-A, -B, and -DR combinations
would be required to match 100% of
potential UK recipients (Figure 1A). The
three highest ranked HLA-A, -B, and -DR
combinations matched 34% of potential
recipients and the 10 highest ranked
homozygous combinations matched
53% of potential recipients. The first 150
theoretical homozygous HLA-A, -B, and
-DR combinations provided a match for
94% of potential recipients and beyond
this, each additional theoretical homozy-
gous HLA-A, -B, and -DR combination
provided an HLA match for only 0.024%
of recipients.
Identification of Potential iPSC
Donors with Optimal Utility for
Banking
We next determined which of the 405
theoretical homozygous HLA combina-
tions described above actually exist by
interrogating the >17 million HLA-typed
Figure 1. Ability of HLA Homozygous Donors to Provide a Zero HLA
Mismatch for HLA Heterozygous Recipients
(A) Potential for a panel of 405 theoretical homozygous HLA combinations to
provide a zero HLAmismatch for all 10,000 potential UK recipients. The cumu-
lative percentage of recipients matched increased steeply with successive
theoretical homozygous HLA combinations ranked for utility, until the panel
exceeded 100–150 combinations.
(B) Ability of an iPSC bank comprising the minimum number of optimal homo-
zygous HLA types (236) known to exist (as volunteer HSC donors on the
BMDW registry) to provide a zero HLA mismatch for all 10,000 potential UK
recipients. The 236 homozygous HLA types were identified among the 405
theoretical homozygousHLA combinations used in panel (A). Again, the cumu-
lative percentage of recipients matched increased steeply with successive
homozygous HLA combinations ranked for utility, but did not exceed 96%
due to the absence of certain theoretical homozygous HLA combinations
among the >17 million volunteers on the BMDW registry.
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registered on Bone Marrow
Donors Worldwide (BMDW)
(http://www.bmdw.org) who
could, in principle, donate
tissue to a future iPSC bank
designed to achieve a zero
HLA-A, -B, and -DR mis-
match for the UK population.
For practical purposes and
to give the greatest chance
that donors might be of blood
group O type (universal
donor), we required each of
the 405 theoretical HLA
combinations to be repre-
sented at least 10 times
among the 17 million volun-
teers. At least 10 HLA homo-
zygous potential iPSC
donors were found for 236
(58.3%) of the 405 theoretical
HLA combinations required,
and these provided a zero
mismatch for 95.48% of
potential UK recipients (Fig-
ure 1B). The top 150 of the
236 highest ranked homozy-
gous HLA types identified
provided a zero HLA mis-
match for 93.16% of poten-
tial UK recipients, with a
maximum of 19,398 and
minimum of 10 potential
donors for the most, and
least, frequent homozygous
HLA donor types, respec-
tively. A stem cell bank popu-
lated with as few as 50 iPSC
lines of the highest-ranked
homozygous HLA types
would provide a zero HLA
mismatch for 79% of poten-
tial UK recipients; these arelisted in Table 1. The entire list of 236
homozygous HLA types ranked in de-
scending order of utility to provide a zero
HLA-A, -B, and -DR mismatch for the
potential UK recipient population can be
found as Table S2B.
Contributions and Limitations of the
Study
The present report has identified, for the
first time, the best possible combination
of theoretical HLA types thatwould provide
a zero HLA-A, -B, and -DRmismatch for all
of thepotential recipientsof iPSCtherapy in
the UK, and has identified which of theseoptimal HLA types actually exist among
volunteer stem cell donors registered on
BMDW. We showed previously, in the
context of embryonic stem cell banking,
that 10 homozygous donors selected
from 10,000 individuals allowed HLA-A,
-B, and -DR matching for 38% of potential
UK recipients (Taylor et al., 2005). Others,
using previously published HLA haplotype
frequencies, have estimated the number
of highly selected donors with favorable
HLA types needed to provide HLA-
matched tissue for a Japanese and a
Chinese recipient population (Nakatsuji
et al., 2008; Okita et al., 2011; Lin et al.,Cell Stem Cell 11, August 32009). These studies may
underestimate the potential
for HLA matching because, for
a fully heterozygous recipient
expressing two HLA haplo-
types, a zero HLA mismatch
can be achieved using eight
possible homozygous donor
HLA combinations. This may,
however, be counterbalanced
by the increased heterogeneity
of HLA-A, -B, and -DR combi-
nations at the allelic level
when encoded by genes that
segregate independently. Pre-
vious studies were also based
on the requirement for large
pools of random donors to be
screened in order to ensure
those with the desired HLA
haplotypes are identified. Fur-
thermore, the conserved HLA
haplotypes identified through
linkage disequilibrium are not
necessarily those HLA combi-
nations thatareofmostbenefit.
The present study overcomes
these limitations and is based
instead on the concept that
iPSCs obtained from adult
donors with the desired homo-
zygousHLA typecan be identi-
fied from existing volunteer
stem cell donor registries. By
calculating all the theoretically
possible homozygous HLA-A,
-B, and -DR combinations
(regardless of linkage disequi-
librium)wewereable to identify
those that provide optimal HLA
matching for the UK popula-
tion, and then determine if indi-
viduals with such homozygous
HLA combinations were regis-tered on the volunteer stem cell donor
registries.
Volunteers listed on the BMDW registry
have only consented to provide hemato-
poietic stem cells (HSCs) for a single
recipient in need of a HSC transplant
and have not been asked to consent for
donation of tissue from which an iPSC
cell bank could be created that had the
future potential to help many thousands
of recipients. The ethics of seeking con-
sent from the donor registry to approach
such individuals and request their consent
for tissue for an iPSC bank would need to
be addressed., 2012 ª2012 Elsevier Inc. 149
Table 1. The 50 Highest Ranked Homozygous HLA-A, -B, and -DR Types Identified on the BMDW Registry that Cumulatively Provide
a Zero HLA Mismatch for 79% of 10,000 Potential UK Recipients
Rank HLA-A HLA-B HLA-DR Recipients Matched (%) Recipients Matched (Cumulative %)
1 A1 B8 DR17(3) 16.87 16.87
2 A2 B44(12) DR4 9.51 26.38
3 A3 B7 DR15(2) 7.45 33.83
4 A2 B7 DR15(2) 4.28 38.11
5 A2 B44(12) DR7 3.41 41.52
6 A2 B62(15) DR4 2.85 44.37
7 A1 B57(17) DR7 2.54 46.91
8 A3 B35 DR1 2.10 49.01
9 A29(19) B44(12) DR7 2.04 51.05
10 A2 B60(40) DR4 1.75 52.80
11 A2 B8 DR17(3) 1.60 54.40
12 A2 B27 DR1 1.28 55.68
13 A2 B44(12) DR13(6) 1.23 56.91
14 A3 B7 DR4 1.20 58.11
15 A1 B8 DR4 0.94 59.05
16 A2 B57(17) DR7 0.93 59.98
17 A2 B60(40) DR13(6) 0.92 60.90
18 A11 B35 DR4 0.89 61.79
19 A2 B44(12) DR11(5) 0.89 62.68
20 A24(9) B7 DR15(2) 0.83 63.51
21 A30(19) B13 DR7 0.81 64.32
22 A31(19) B60(40) DR4 0.79 65.11
23 A3 B7 DR1 0.77 65.88
24 A11 B35 DR1 0.70 66.58
25 A3 B65(14) DR13(6) 0.67 67.25
26 A1 B8 DR15(2) 0.67 67.92
27 A2 B44(12) DR15(2) 0.65 68.57
28 A2 B51 DR11(5) 0.64 69.21
29 A3 B44(12) DR4 0.63 69.84
30 A2 B62(15) DR13(6) 0.60 70.44
31 A2 B7 DR4 0.59 71.03
32 A25(10) B18 DR15(2) 0.59 71.62
33 A24(9) B62(15) DR4 0.55 72.17
34 A1 B7 DR15(2) 0.54 72.71
35 A32(19) B64(14) DR7 0.52 73.23
36 A2 B27 DR4 0.48 73.71
37 A2 B18 DR17(3) 0.45 74.16
38 A1 B44(12) DR4 0.45 74.61
39 A2 B13 DR7 0.43 75.04
40 A3 B60(40) DR4 0.41 75.45
41 A2 B44(12) DR1 0.40 75.85
42 A24(9) B44(12) DR7 0.40 76.25
43 A2 B35 DR11(5) 0.38 76.63
44 A29(19) B44(12) DR15(2) 0.37 77.00
45 A1 B8 DR1 0.35 77.35
46 A3 B7 DR7 0.34 77.69
47 A3 B8 DR17(3) 0.34 78.03
48 A11 B51(5) DR4 0.33 78.36
49 A3 B44(12) DR13(6) 0.31 78.67
50 A2 B62(15) DR1 0.31 78.98
150 Cell Stem Cell 11, August 3, 2012 ª2012 Elsevier Inc.
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analysis. First, HLA matching was based
on HLA types defined at the highest spec-
ificity level for the three most relevant loci
known to influence graft rejection (HLA-A,
-B, and -DR). This does not ensure HLA
matching at the allelic level for these loci
or matching for other loci, including
HLA-C, -DQ, and -DP, that may also
contribute to rejection. However, in
many cases, linkage disequilibrium of
conserved HLA haplotypes will ensure
an allelic match at all loci. The risk of
HLA-DQ mismatches would be higher
with -DR4, -DR7, and -DR13 haplotypes.
While there is no known role for HLA-DQ
matching in organ transplantation, -DQ
mismatches would be particularly rele-
vant for patients with HLA-DQ-specific
antibodies that may occur naturally
(through crossreactivity with microbial
antigens) or after exposure to HLA alloan-
tigens through pregnancy and/or blood
transfusion.
HLA polymorphism can be resolved at
the level of serologically defined specific-
ities that correspond to ‘‘low resolution’’
(two-digit) HLA typing, or at amino acid
sequence level (high resolution/four-digit
allele) HLA typing. The low resolution level
of HLA matching applied in the present
study is known to give the maximum
benefit for tissue and organ transplanta-
tion. This contrasts with the more strin-
gent HLA allele level matching required
in allogeneic bonemarrow transplantation
to minimize the risk of graft versus host
disease (GvHD). However, for the three
highest ranked homozygous HLA types
identified (Table 1), two (HLA-A1, -B8,
and -DR17(3) and HLA-A3, -B7, and
-DR15(2)) are highly conserved at the
allele (four-digit) level and include HLA-C
and -DQ linkage at a ratio >95%. In
contrast, HLA-A2, -B44(12), and -DR4 is
heterogeneous and may comprise
different HLA-B, -C, -DR, and -DQ allelic
combinations. Where heterogeneity
exists within an HLA haplotype it is
possible to achieve a higher degree of
matching by populating an iPSC bank
with HLA homozygous lines that repre-
sent the different HLA allele combinations
as illustrated in Table S2A. However, the
concerns regarding allele-level matching
relate particularly to allogeneic HSC
transplantation, but not to iPSC trans-
plantation, where GvHD will not occur
because mature T lymphocytes wouldnot be a graft component. Moreover, in
the case of HSCs derived from iPSCs, it
is not conceivable that GvHD could occur
because T cells would only become allor-
eactive after selection and maturation in
the donor thymus gland, which of course
would not occur. It is likely that iPSC
tissue matched only at the HLA specificity
level would require immunosuppression
to prevent graft rejection. Even grafts
matched at HLA-A, -B, and -DR may
require immunosuppression, which, in
the case of solid organ transplants, typi-
cally comprises a calcineurin inhibitor
(Cyclosporin or Tacrolimus) combined
with steroids and an antiproliferative
agent (Azathioprine or mycophenolic
acid). Long-term immunosuppression,
although highly effective, is associated
with increased risk of infection and certain
types of malignancy, notably squamous
cell carcinoma and lymphoma. It should,
however, be noted that iPSC-derived
tissue would lack highly immunogenic
dendritic cells, which are a major stimu-
lator of the rejection response, while ex-
pression of MHC class II is absent from
iPSC and embryoid bodies, even when
cultured in the presence of interferon-
gamma. Indeed, DNA methylation and
histone modification studies of iPSCs
imply tight epigenetic regulation of MHC
expression, possibly emerging as a sur-
vival mechanism during embryogenesis
(Sua´rez-Alvarez et al., 2010).
A further limitation to our approach is
that the 236 homozygous HLA types
identified to provide an HLA match for
potential UK recipients (of predominantly
white European ethnicity) would not
necessarily be those that would provide
the best HLA match for countries where
there was a predominance of individuals
from other ethnic groups, although in
some cases there would be considerable
overlap for certain conserved HLA haplo-
types. For example, two HLA haplotypes
identified by Okita et al. (2011) (HLA-
A24, -B52, and -DR15 and HLA-A11,
-B62, and -DR4) are present in 8.5% and
1.3%, respectively, of the Japanese
population and match around 20% of
Japanese individuals, but these would
provide little utility for the UK population
as neither haplotype featured in the
optimal combination of 236 homozygous
HLA types reported in our present study.
Furthermore, Okita et al. (2011) estimated
that 160,000 healthy volunteer iPSCCell Stem Cell 1donors would be required to identify the
140 unique HLA homozygous iPSC
donors that would match 90% of the
Japanese population. Using the approach
that we describe in the present study, we
identified 3,797 and 227 volunteers regis-
tered on BMDW that are reported as
homozygous HLA-A24, -B52, and -DR15
and HLA-A11, -B62, and -DR4, respec-
tively, thereby providing an immediate
and identifiable source of potential iPSC
donors that have the required HLA types,
without the need to HLA type many thou-
sands of volunteers from the Japanese
population.
Notably, of the 10,000 HLA typed organ
donors used in our present study to repre-
sent the UK population, only 217 (2%)
were identified as ‘‘nonwhite’’ ethnicity
(98 Asian, 60 black, 13 Oriental, 27 mixed
race, and 19 other). The three highest
ranking homozygous HLA types (Table 1)
that matched 34% of the entire 10,000
cohort only matched 22 (10%) of 217
nonwhites, indicating that the optimal
homozygous HLA types required to popu-
late an iPSC bank would differ for different
ethnic groups both within and between
countries. This finding should encourage
policymakers to use this approach to
identify and select the optimal HLA-typed
volunteer donors to match a potential
iPSC recipient population of specific
ethnicity.
Concluding Remarks
The findings from this study provide
a potential solution for populating a thera-
peutic iPSC bank with a relatively small
number of lines that will enable an HLA
match for the majority of a potential recip-
ient population, thereby reducing the
problem of allograft rejection after trans-
plantation. To pursue this approach
would necessitate extensive consultation
and agreement from national and interna-
tional volunteer HSC donor registries. The
ethics of seeking consent from individuals
with the required HLA types for donation
of tissue (e.g., blood or skin biopsy) from
which iPSCs could be derived requires
careful consideration.
However, such volunteers have already
expressed their willingness to donate
HSCs harvested from blood or bone
marrow to treat a single anonymous indi-
vidual. In the case of iPSC therapy, the
opportunity for selected volunteers to
help a potentially unlimited number of1, August 3, 2012 ª2012 Elsevier Inc. 151
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Synthesispatients might be an attractive and
achievable proposition.
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